ImmunisBio Accelerates Stem Cell Business Expansion... Secures Related Patents

[Asia Economy Reporter Hyungsoo Park] Immunis Bio announced on the 8th that through its subsidiary Smart Cell Lab, it has signed a patent acquisition contract for 16 patents related to stem cells and devices, including ‘Induction of differentiation of ellipticine stem cells into chondrocytes,’ owned by the Industry-Academic Cooperation Foundation of Catholic Kwandong University.

Smart Cell Lab researches and develops disease-specific stem cell therapeutics, autologous stem cells, immune cells, and next-generation drugs based on m-RNA.

Among the acquired patents are those related to controlling the expression of stem cell growth factors and mass production, stem cell differentiation, and stem cell culture devices and systems. Two patents for differentiation induction are currently undergoing PCT international patent applications.

Kang Jung-hwa, CEO of Smart Cell Lab, introduced, "We are developing stem cell therapeutics that replace existing stem cell treatments, with no rejection after transplantation and a 100% functional regulation rate."

She added, "The scope is expected to expand to include drugs and diagnostic kits that prevent arrhythmia and angina, patient-customized cell therapeutics, as well as the stem cell procedure market."

In the cosmeceutical sector, related patented technologies that mass-produce stem cell growth factors and improved active ingredients will also be utilized. Products effective for whitening, wrinkle improvement, antioxidation, and hair growth are being prepared for launch. The safety and functional effects of the active ingredients have also been confirmed. It is known that various applied products using stem cells are also being considered for future release.

The Biotechnology Policy Research Center forecasted that the domestic stem cell market, which formed a market of about $2.3 billion last year, will grow at an average annual rate of about 26% to reach $4.7 billion in 2022. Through the patent acquisition, Smart Cell Lab has laid the foundation to expand its business in the domestic stem cell market to include cell therapeutics, cosmeceuticals, and procedure fields.

Hwang Sung-hwan, CEO of Immunis Bio, said, "Through technology transfer, we have taken a step forward in developing regenerative medicine cell therapeutics and cosmeceuticals," adding, "We will commercialize the secured technologies and develop business models related to personalized cell therapeutics and cosmeceuticals."

This content was produced with the assistance of AI translation services.